Braga, Portugal Clinical Trials

A listing of Braga, Portugal clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 4 clinical trials
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment extension in moderate-to-severe ulcerative colitis (CALDOSE-1).

flexible sigmoidoscopy
tumor necrosis factor
tumor necrosis factor alpha
Hospital da Senhora da Oliveira - Guimar es, EPE
 (9.4 away) Contact site
  • 11 Jun, 2021
  • +189 other locations
Efficacy and Safety of TD-1473 in Crohn's Disease

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.

tumor necrosis factor
conventional treatment
crohn's disease
Theravance Biopharma Investigational Site
 (0.3 away) Contact site
  • 28 Jan, 2021
  • +208 other locations
The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.

her2/neu-negative breast cancer
endocrine therapy
Hospital de Braga-Escala Braga
 (2.0 away) Contact site
  • 09 Jun, 2021
  • +146 other locations
A Study of TAR-200 in Combination With Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.

carcinoma in situ
intravesical bcg
transurethral resection
transurethral bladder excision
Hospital da Senhora da Oliveira
 (9.4 away) Contact site
  • 28 May, 2021
  • +174 other locations